PURPOSE: Low concentrations of 25-hydroxyvitamin D3 (25(OH)D) have been associated with increased risk and poor prognosis of various cancer types, including colon cancer. Common genetic variants in genes that influence circulating 25(OH)D levels may affect vitamin D concentrations and risk of vitamin D insufficiency. In the present study, we investigated the association of three functional gene variants in GC (rs2282679 T>G), DHCR7 (rs12785878 G>T) and CYP2R1 (rs10741657 A>G) with time to recurrence (TTR) in patients with stages II and III colon cancer. METHODS: Two hundred and sixty-four patients were included in this retrospective study. Genomic DNA was genotyped for GC rs2282679 T>G, DHCR7 rs12785878 G>T and CYP2R1 rs10741657 A>G by 5'-exonuclease (TaqMan™) technology. RESULTS: In the univariate analysis, GC rs2282679 GG was significantly associated with decreased TTR (HR = 3.30, 95 % CI 1.09-9.97, p = 0.034) in patients with surgery alone and remained significantly associated in multivariate analysis including lymph node involvement and clinical stage (HR = 3.64, 95 % CI 1.16-11.46, p = 0.027). In patients with adjuvant chemotherapy, GC rs2282679 T>G was not significantly associated with TTR (HR = 1.02, 95 % CI 0.44-2.37, p = 0.964). Furthermore, we observed a trend toward decreased TTR in patients harboring the CYP2R1 rs10741657 A>G gene variant including all patients (HR = 1.50, 95 % CI 0.98-2.28, p = 0.060). No association was found between DHCR7 rs12785878 G>T and TTR in our study cohort. CONCLUSION: In conclusion, our results may indicate a prognostic effect of GC rs2282679 in stages II and III colon cancer patients with surgery alone. Larger studies have to be performed to validate our findings.
PURPOSE: Low concentrations of 25-hydroxyvitamin D3 (25(OH)D) have been associated with increased risk and poor prognosis of various cancer types, including colon cancer. Common genetic variants in genes that influence circulating 25(OH)D levels may affect vitamin D concentrations and risk of vitamin Dinsufficiency. In the present study, we investigated the association of three functional gene variants in GC (rs2282679 T>G), DHCR7 (rs12785878 G>T) and CYP2R1 (rs10741657 A>G) with time to recurrence (TTR) in patients with stages II and III colon cancer. METHODS: Two hundred and sixty-four patients were included in this retrospective study. Genomic DNA was genotyped for GC rs2282679 T>G, DHCR7rs12785878 G>T and CYP2R1rs10741657 A>G by 5'-exonuclease (TaqMan™) technology. RESULTS: In the univariate analysis, GC rs2282679 GG was significantly associated with decreased TTR (HR = 3.30, 95 % CI 1.09-9.97, p = 0.034) in patients with surgery alone and remained significantly associated in multivariate analysis including lymph node involvement and clinical stage (HR = 3.64, 95 % CI 1.16-11.46, p = 0.027). In patients with adjuvant chemotherapy, GC rs2282679 T>G was not significantly associated with TTR (HR = 1.02, 95 % CI 0.44-2.37, p = 0.964). Furthermore, we observed a trend toward decreased TTR in patients harboring the CYP2R1rs10741657 A>G gene variant including all patients (HR = 1.50, 95 % CI 0.98-2.28, p = 0.060). No association was found between DHCR7rs12785878 G>T and TTR in our study cohort. CONCLUSION: In conclusion, our results may indicate a prognostic effect of GC rs2282679 in stages II and III colon cancerpatients with surgery alone. Larger studies have to be performed to validate our findings.
Authors: A L Lauridsen; P Vestergaard; A P Hermann; C Brot; L Heickendorff; L Mosekilde; E Nexo Journal: Calcif Tissue Int Date: 2005-05-05 Impact factor: 4.333
Authors: Amy A Irving; Richard B Halberg; Dawn M Albrecht; Lori A Plum; Kathleen J Krentz; Linda Clipson; Norman Drinkwater; James M Amos-Landgraf; William F Dove; Hector F DeLuca Journal: Arch Biochem Biophys Date: 2011-09-01 Impact factor: 4.013
Authors: H G Pálmer; J M González-Sancho; J Espada; M T Berciano; I Puig; J Baulida; M Quintanilla; A Cano; A G de Herreros; M Lafarga; A Muñoz Journal: J Cell Biol Date: 2001-07-23 Impact factor: 10.539
Authors: Sarah-Michelle Orton; Andrew P Morris; Blanca M Herrera; Sreeram V Ramagopalan; Matthew R Lincoln; Michael J Chao; Reinhold Vieth; A Dessa Sadovnick; George C Ebers Journal: Am J Clin Nutr Date: 2008-08 Impact factor: 7.045
Authors: Mazda Jenab; H Bas Bueno-de-Mesquita; Pietro Ferrari; Franzel J B van Duijnhoven; Teresa Norat; Tobias Pischon; Eugène H J M Jansen; Nadia Slimani; Graham Byrnes; Sabina Rinaldi; Anne Tjønneland; Anja Olsen; Kim Overvad; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Sophie Morois; Rudolf Kaaks; Jakob Linseisen; Heiner Boeing; Manuela M Bergmann; Antonia Trichopoulou; Gesthimani Misirli; Dimitrios Trichopoulos; Franco Berrino; Paolo Vineis; Salvatore Panico; Domenico Palli; Rosario Tumino; Martine M Ros; Carla H van Gils; Petra H Peeters; Magritt Brustad; Eiliv Lund; María-José Tormo; Eva Ardanaz; Laudina Rodríguez; Maria-José Sánchez; Miren Dorronsoro; Carlos A Gonzalez; Göran Hallmans; Richard Palmqvist; Andrew Roddam; Timothy J Key; Kay-Tee Khaw; Philippe Autier; Pierre Hainaut; Elio Riboli Journal: BMJ Date: 2010-01-21
Authors: Sonja Neumeyer; Katja Butterbach; Barbara L Banbury; Sonja I Berndt; Peter T Campbell; Rowan T Chlebowski; Andrew T Chan; Edward L Giovannucci; Amit D Joshi; Shuji Ogino; Mingyang Song; Marjorie L McCullough; Haifa Maalmi; JoAnn E Manson; Lori C Sakoda; Robert E Schoen; Martha L Slattery; Emily White; Aung K Win; Jane C Figueiredo; John L Hopper; Finlay A Macrae; Ulrike Peters; Hermann Brenner; Michael Hoffmeister; Polly A Newcomb; Jenny Chang-Claude Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-03-18 Impact factor: 4.254
Authors: P G Vaughan-Shaw; F O'Sullivan; S M Farrington; E Theodoratou; H Campbell; M G Dunlop; L Zgaga Journal: Br J Cancer Date: 2017-03-16 Impact factor: 7.640
Authors: Yun Zhu; Peizhong Peter Wang; Guangju Zhai; Bharati Bapat; Sevtap Savas; Jennifer R Woodrow; Peter T Campbell; Yuming Li; Ning Yang; Xin Zhou; Elizabeth Dicks; John R Mclaughlin; Patrick S Parfrey Journal: BMC Cancer Date: 2018-02-06 Impact factor: 4.430